

Resource Summary Report

Generated by SPARC SAWG on Aug 20, 2026

CD8? (D8A8Y) Rabbit mAb

RRID:AB_2800052

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 85336, RRID:AB_2800052

Antibody Information

URL: http://antibodyregistry.org/AB_2800052

Proper Citation: Cell Signaling Technology Cat# 85336, RRID:AB_2800052

Target Antigen: CD8A

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, F

Antibody Name: CD8? (D8A8Y) Rabbit mAb

Description: This monoclonal targets CD8A

Target Organism: h

Clone ID: Clone D8A8Y

Antibody ID: AB_2800052

Vendor: Cell Signaling Technology

Catalog Number: 85336

Record Creation Time: 20250819T204828+0000

Record Last Update: 20250819T205323+0000

Ratings and Alerts

No rating or validation information has been found for CD8? (D8A8Y) Rabbit mAb.

No alerts have been found for CD8? (D8A8Y) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Geng H, et al. (2026) Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy. *Developmental cell*, 61(5), 995.

Zhu L, et al. (2026) A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer. *Cancer discovery*, 16(7), 1360.

He G, et al. (2026) Vesicle trafficking 1 in breast cancer tissue and serum orchestrates metastatic progression and an immunosuppressive microenvironment. *International immunopharmacology*, 178, 116564.

Yan X, et al. (2026) Activation of T Cell-Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy. *Cancer discovery*, 16(1), 155.

Chen Z, et al. (2026) Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma. *Cell reports. Medicine*, 7(4), 102712.

Jiang X, et al. (2026) USP20-Driven Cholesterol Metabolism Links Inflammatory Signaling to Malignancy and Stromal Coevolution in Pancreatic Cancer. *Cancer research*, 86(3), 712.

Hladik C, et al. (2026) Spatially Resolved Obesity-Driven Molecular Changes in Early Breast Cancer. *The American journal of pathology*, 196(7), 1471.

Yoshichika R, et al. (2026) Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer. *Cancer immunology, immunotherapy : CII*, 75(4).

Guo D, et al. (2026) Lactate binds and inhibits the innate immune sensor STING to promote tumor immune evasion. *Immunity*, 59(7), 1811.

Zhao Z, et al. (2025) Sickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. *Immunity*, 58(6), 1484.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. *Cell reports. Medicine*, 6(3), 101977.

Liu HM, et al. (2025) Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. *Cell*

reports. *Medicine*, 6(2), 101930.

Han S, et al. (2025) Inhibition of KAT6A enhances immunotherapy efficacy in colorectal cancer by activating interferon response. *Cancer letters*, 631, 217946.

Zhu B, et al. (2025) Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. *Cancer cell*, 43(6), 1125.

Wang Y, et al. (2025) Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy. *Cell reports. Medicine*, 6(12), 102473.

Wang Y, et al. (2025) AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunity. *Cell reports*, 44(4), 115445.

Oh J, et al. (2025) Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer. *Cell reports. Medicine*, 6(5), 102100.

Han S, et al. (2025) USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment. *Cancer immunology research*, 13(8), 1226.

Paulsohn MB, et al. (2025) Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. *Cell death & disease*, 17(1), 129.

Mi Z, et al. (2024) Cellular and molecular determinants of bacterial burden in leprosy granulomas revealed by single-cell multimodal omics. *EBioMedicine*, 108, 105342.